Topics

GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results

19:00 EST 6 Nov 2019 | Globe Newswire

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third quarter ended September 30, 2019.

“With the recent FDA acceptance of our NDA filing for voxelotor, we are an important step closer to potentially transforming the treatment paradigm for sickle cell disease. We remain focused on our launch preparations, including the buildout of our commercial organization with the hiring of the entire field team, and steadfast in our mission to deliver to the sickle cell community a breakthrough therapy that has the potential to modify the course of this complex disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We remain on track to initiate our post-approval confirmatory study of voxelotor, which utilizes transcranial Doppler flow velocity as the primary endpoint, prior to year-end. We also look forward to sharing several post-hoc analyses of data from the HOPE Study, as well as other sickle cell disease research, at the upcoming ASH Annual Meeting.”

Recent Business Progress

Sickle Cell Disease (SCD)

  • Announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) seeking accelerated approval for voxelotor for the treatment of SCD. The FDA granted the NDA Priority Review and assigned a Prescription Drug User Fee Act target action date of February 26, 2020.
  • Hired 65 Sickle Cell Therapeutic Specialists, bringing the company’s field team to approximately 75 members.
  • Received acceptance of eight abstracts at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held December 7-10 in Orlando.
  • Presented results of the first of several planned post-hoc analyses of data from the Phase 3 HOPE Study. The findings suggest that voxelotor resolved or reduced the severity of existing leg ulcers and decreased the incidence of new leg ulcers in patients with SCD. The exploratory post-hoc analysis was presented at the 13th Annual Academy for Sickle Cell and Thalassemia Conference in London.
  • Presented four abstracts and sponsored a lunch symposium during the 47th Annual National Sickle Cell Disease Association of America Convention in Baltimore.
  • Hosted two SCD-focused conferences:
    -- The 2019 SCD Access to Care Summit in Washington, D.C., which brought together members of the SCD community to discuss solutions toward improving access to care; and
    -- The 8th Annual SCD Therapeutics Conference, which highlighted the latest medical advances and future trends in the treatment of patients with SCD.

Corporate

  • Appointed three members of the company’s senior management team to the following positions:
    -- Josh Lehrer, M.D., to chief medical officer. Dr. Lehrer has played a critical role in overseeing the clinical development of voxelotor since he joined the company in 2013.
    -- Peter Radovich to executive vice president, operations. Mr. Radovich has led the manufacturing, quality assurance and project management functions for GBT since he joined the company in 2014 and has been integral to the development of voxelotor.
    -- Jonathan Sorof, M.D., to senior vice president, head of medical affairs and program team leader, voxelotor. Dr. Sorof has made tremendous contributions in building the medical and regulatory affairs teams since he joined the company in 2017.

Financial Results for the Three Months Ended September 30, 2019
Cash, cash equivalents and marketable securities totaled $683.1 million at September 30, 2019, compared with $591.8 million at December 31, 2018.

Net loss for the three months ended September 30, 2019, was $64.5 million compared with $43.1 million for the same period in 2018. Basic and diluted net loss per share for the three months ended September 30, 2019, was $1.07 compared with $0.83 for the same period in 2018. Operating expenses increased from the second quarter to the third quarter of 2019. GBT continues to expect its net loss to significantly increase in the fourth quarter of 2019. The increase will be primarily driven by expenses related to the continued buildout of the company’s commercial infrastructure as it prepares for the potential commercial launch of voxelotor, the expansion of its manufacturing efforts for voxelotor, the commencement of additional clinical studies of voxelotor in SCD, and the advancement of its pipeline programs, including its inclacumab program.

Research and development (R&D) expenses for the three months ended September 30, 2019, were $39.1 million compared with $33.0 million for the same period in 2018. The increase in R&D expenses is primarily attributable to increased employee-related costs, including non-cash stock compensation expense, and increased costs associated with NDA submission activities. Total R&D non-cash stock compensation expense incurred for the three months ended September 30, 2019, was $5.1 million compared with $2.8 million for the same period in 2018.

General and administrative (G&A) expenses for the three months ended September 30, 2019, were $29.7 million compared with $12.5 million for the same period in 2018. The increase in G&A expenses is primarily attributable to increased employee-related costs, including non-cash stock compensation expense, and increased professional and consulting services associated with the buildout of the company’s commercial operations. Total G&A non-cash stock compensation expense incurred in the three months ended September 30, 2019, was $7.3 million compared with $4.1 million for the same period in 2018.

About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about GBT’s development plans for voxelotor and the potential benefits of voxelotor for SCD patients and other statements containing the words “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding delivering a breakthrough therapy that has the potential to modify the course of SCD, regulatory review and actions relating to voxelotor, including the availability of and sufficiency of data to support accelerated regulatory approval of voxelotor, the therapeutic potential and safety profile of voxelotor for SCD, including the potential to be a disease-modifying therapy, to transform the treatment paradigm and to become a new standard of care, implementing and completing clinical development plans for voxelotor, generating and reporting data and analyses from past, ongoing and potential future studies of voxelotor, the potential commercial launch of voxelotor, GBT’s commercial infrastructure and manufacturing efforts, GBT’s pipeline programs, GBT’s future financial results, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about GBT’s plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control including, without limitation, the risks that GBT’s clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with GBT’s clinical development plans or require additional studies or data to support further clinical investigation of GBT’s product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

GLOBAL BLOOD THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2019 2018 2019 2018
Operating expenses:       
Research and development$39,088  $33,026  $109,564  $94,543 
General and administrative29,654  12,450  72,503  36,115 
Total operating expenses68,742  45,476  182,067  130,658 
Loss from operations(68,742) (45,476) (182,067) (130,658)
Other income (expense):           
Interest income, net4,226  2,480  11,422  5,768 
Other expenses, net(31) (72) (146) (101)
Total other income, net4,195  2,408  11,276  5,667 
Net loss$(64,547) $(43,068) $(170,791) $(124,991)
Basic and diluted net loss per common share$(1.07) $(0.83) $(2.96) $(2.47)
Weighted-average number of shares used in computing basic and diluted net loss per common share60,098,093  52,050,232  57,637,318  50,536,860 
            

GLOBAL BLOOD THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(In thousands)

  September 30, 2019 December 31, 2018
   (Unaudited)   
Assets        
Current assets:        
Cash and cash equivalents $267,604  $275,357 
Short-term marketable securities  335,500   202,177 
Prepaid expenses and other current assets  12,699   8,246 
Total current assets  615,803   485,780 
Property and equipment, net  14,337   14,981 
Long-term marketable securities  80,000   114,281 
Operating lease right-of-use assets  13,845    
Other assets  3,363   2,601 
Total assets $727,348
  $617,643 
Liabilities and Stockholders’ Equity        
Current liabilities $
41,193  $
33,773 
Operating lease liabilities, noncurrent  23,691    
Other liabilities, noncurrent  4,367   11,071 
Total liabilities  69,251   44,844 
Total stockholders’ equity  658,097   572,799 
Total liabilities and stockholders’ equity $727,348  $617,643 

Contact Information:
Stephanie Yao (investors)
GBT
650-741-7730
investor@gbt.com

Steven Immergut (media)
GBT
650-410-3258
media@gbt.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...